Some of the names on the move ahead of the open.» Read More
SAN FRANCISCO/ NEW YORK, April 10- Carl Icahn backed off calls for eBay Inc to spin out its fast-growing PayPal payments unit on Thursday, after the billionaire investor failed to drum up support from the e-commerce company's major shareholders. Icahn withdrew his two nominees to eBay's board ahead of the company's annual meeting in May.
The S&P has made an all-time high for nine-straight quarters, but CNBC's Jim Cramer says there's reason to think it's sustainable.
Some of the names on the move ahead of the open.
*Morgan Stanley tops global rankings. LONDON, March 28- A string of large transactions drove the value of global mergers and acquisitions activity up by 54 percent in the first quarter compared to the same period last year, reflecting greater deal-making confidence among chief executives.
MUMBAI, March 6- Sun Pharmaceutical Industries Ltd, India's biggest drugmaker by market value, is looking for partnerships or acquisitions to enter Japan, an especially lucrative market for manufacturers of low-cost drugs, a senior executive said.
Feb 27- Valeant Pharmaceuticals International Inc sees close to 50 opportunities for mergers or acquisitions, its chief executive said on Thursday, as it aims to become one of the world's five biggest pharmaceutical companies.
NEW YORK, Feb 24- Billionaire investor Carl Icahn accused eBay Inc Chief Executive John Donahoe of failing to spot- or ignoring- conflicts of interest on the company's board and called again for the spinoff of its fast-growing PayPal payments business.
Feb 24- Billionaire investor Carl Icahn accused eBay Inc Chief Executive John Donahoe of failing to spot- or ignoring- conflicts of interest on the company's board and called again for the spinoff of its fast-growing PayPal division.
Feb 24- Billionaire investor Carl Icahn accused eBay Inc Chief Executive John Donahoe of failing to spot- or ignoring- conflicts of interest on the company's board and called again for the spinoff of its fast-growing PayPal division. Marc Andreessen and Scott Cook, both long-term eBay board members, bore the brunt of Icahn's conflict allegations.
With three mergers totaling more than $110 billion in just the past week, 2014 could be the year of the megamerger, as cash-rich companies hunt for growth.
Stocks finished near session lows in volatile trading Wednesday, with the Nasdaq snapping an eight-day winning streak, as investors digested minutes from the Fed's latest policy meeting.
Despite his mild concern, influential investor Dennis Gartman says it's still a bull market for stocks.
Feb 18- After a nearly three-year campaign at Forest Laboratories Inc that spanned two proxy battles and the ousting of a chief executive, billionaire activist investor Carl Icahn has once again ended up on top.
Stocks mostly rose on Tuesday amid a large acquisition and data disregarded as weather related.
*Forest Labs shares soar; Actavis agrees to buy company. NEW YORK, Feb 18- The S&P 500 and Nasdaq rose on Tuesday, following Wall Street's biggest weekly gain of the year, as merger activity increased confidence that there is value in the stock market even as the benchmark index nears a record high.
*Forest Labs shares jump, Actavis to purchase. NEW YORK, Feb 18- U.S. stocks edged up on Tuesday, following Wall Street's biggest gain of the year, as merger activity boosted confidence there is still value in the market even as the S&P 500 nears a record high.
*Forest Labs surges after Actavis confirms acquisition. "Much of the recent concern over the health of the U.S. economy has been explained at the hands of the weather," said Andrew Wilkinson, chief market analyst at Interactive Brokers LLC in Greenwich, Connecticut.
Actavis agreed to acquire rival drug maker Forest Laboratories in a deal worth as much as $25 billion.
*Forest Labs surges after Actavis confirms acquisition. NEW YORK, Feb 18- U.S. stocks were little changed on Tuesday after Wall Street's biggest gain of the year as disappointing economic reports weighed on investor sentiment.
Feb 18- Generic drugmaker Actavis Plc said on Tuesday it would buy Forest Laboratories Inc for about $25 billion in cash and stock, expanding its portfolio of specialty pharmaceuticals for neurological and other disorders. Actavis said it would pay the equivalent of $89.48 per share, representing a premium of 25 percent to Forest's closing price on Friday.